Vera Therapeutics (VERA) Price & Analysis

Compare

769 Followers

VERA Stock Chart & Stats

$40.42

-$0.18(-0.43%)

At close: Jan 08 4:00 PM EST

$40.42

-$0.18(-0.43%)

Day’s Range― - ―

52-Week Range$18.53 - $56.05

Previous CloseN/A

Volume142.65K

Average Volume (3M)954.86K

Market Cap

$2.88B

Enterprise Value$2.55B

Total Cash (Recent Filing)$714.59M

Total Debt (Recent Filing)$77.31M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

May 07, 2026

EPS Estimate

-1.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.39

Shares Outstanding71,355,670

10 Day Avg. Volume911,914

30 Day Avg. Volume954,860

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)5.38

Price to Sales (P/S)0.00

P/FCF Ratio-13.46

Enterprise Value/Market Cap0.89

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-8.90

Forecast

1Y Price Target

$77.25

Price Target Upside91.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-5.05

Revenue Forecast (FY)$44.09M

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And SafetyPhase III pivotal data showed substantial reductions in proteinuria and consistent benefits across patient subgroups, with no increase in serious adverse events versus placebo, reinforcing a strong benefit‑risk profile.

Market Opportunity And PricingPotential for broad labeling without a proteinuria cutoff combined with favorable competitor pricing could expand the addressable IgA nephropathy market and support significant upside to revenue expectations.

Regulatory ReviewFDA acceptance of the biologics license application with Priority Review and an assigned PDUFA increases the likelihood of a timely approval for atacicept, supporting a clear pathway to commercialization.

Bears Say

Analyst Conflicts Of InterestInvestment banking and market‑making relationships between some firms and the company create potential conflicts that may affect the perceived objectivity of analyst reports and investor confidence.

Funding Risk And Cash RunwayHigh operating cash burn and a limited cash runway increase the risk that additional financing will be needed before material product revenues, which could dilute shareholders or pressure the stock.

Treatment TolerabilityHigher incidence of injection site reactions with the therapy could reduce patient acceptance and limit uptake among patients and clinicians prioritizing tolerability.

Vera Therapeutics News

3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

23h ago

UPB

VERA

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $110 from $90 and keeps a...

1d ago

VERA

Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)

“In 2025, Vera Therapeutics (VERA) delivered on several key milestones as we advanced atacicept toward potential FDA approval...

5d ago

VERA

Vera Therapeutics sees cash runway through atacicept commercial launch

Vera Therapeutics (VERA) reported $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025,...

5d ago

VERA

Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Vera Therapeutics. The associated price target...

4d ago

VERA

Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on VERA stock, giving a Buy rating yesterday....

4d ago

VERA

Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity

Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from...

5d ago

VERA

Vera Therapeutics appoints Skelton as Chief Commercial Officer

Vera Therapeutics (VERA) announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Skelton joined Vera...

1M ago

VERA

Buy Rating on Vera: De-Risked Atacicept Approval Path and Large IgA Nephropathy Market Drive Compelling Upside into 2026 Catalysts

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics, with...

2M ago

VERA

Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

Vera Therapeutics (VERA) announced the atacicept Biologics License Application, BLA, for the treatment of adults with immunoglobulin A...

2M ago

VERA

Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’

As previously reported, Wolfe Research analyst Andy Chen upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Peer Perform with...

2M ago

VERA

VRTX

Short Report: Vera Therapeutics bears retreat as stock rallies

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

2M ago

MBLY

MDGL

Vera Therapeutics price target raised to $66 from $48 at BofA

BofA raised the firm’s price target on Vera Therapeutics (VERA) to $66 from $48 and keeps a Buy...

2M ago

VERA

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Vera Therapeutics (VERA) to $95 from $55 and keeps a...

2M ago

VERA

VERA FAQ

What was Vera Therapeutics’s price range in the past 12 months?

Vera Therapeutics lowest stock price was $18.53 and its highest was $56.05 in the past 12 months.

What is Vera Therapeutics’s market cap?

Vera Therapeutics’s market cap is $2.88B.

When is Vera Therapeutics’s upcoming earnings report date?

Vera Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 65 days.

How were Vera Therapeutics’s earnings last quarter?

Vera Therapeutics released its earnings results on Feb 26, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.325 by -$0.065.

Is Vera Therapeutics overvalued?

According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vera Therapeutics pay dividends?

Vera Therapeutics does not currently pay dividends.

What is Vera Therapeutics’s EPS estimate?

Vera Therapeutics’s EPS estimate is -1.32.

How many shares outstanding does Vera Therapeutics have?

Vera Therapeutics has 71,355,670 shares outstanding.

What happened to Vera Therapeutics’s price movement after its last earnings report?

Vera Therapeutics reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.325. Following the earnings report the stock price went up 1.607%.

Which hedge fund is a major shareholder of Vera Therapeutics?

Currently, no hedge funds are holding shares in VERA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vera Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-50.71%

Trailing 12-Months

Asset Growth

12.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics (VERA) Earnings & Revenues

Historic Earnings Reports

VERA Stock 12 Month Forecast

Average Price Target

$77.25

▲(91.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","42":"$42","65":"$65","88":"$88","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,42,65,88,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.42,45.77230769230769,51.12461538461538,56.47692307692308,61.82923076923077,67.18153846153845,72.53384615384616,77.88615384615385,83.23846153846154,88.59076923076923,93.94307692307692,99.29538461538462,104.64769230769231,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.42,43.253076923076925,46.08615384615385,48.91923076923077,51.752307692307696,54.58538461538462,57.41846153846154,60.25153846153846,63.08461538461539,65.9176923076923,68.75076923076924,71.58384615384615,74.41692307692307,{"y":77.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.42,39.84923076923077,39.27846153846154,38.70769230769231,38.136923076923075,37.566153846153846,36.995384615384616,36.424615384615386,35.853846153846156,35.283076923076926,34.71230769230769,34.14153846153846,33.57076923076923,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >